Compile Data Set for Download or QSAR
maximum 50k data
Found 316 of ph data with Target = 'Cyclin-dependent kinase 2'
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50223567(3-bromo-5-(2-chlorophenyl)-N-(pyridin-3-ylmethyl)p...)
Affinity DataIC50:  3nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129353(US8802686, 11)
Affinity DataIC50:  3nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM6145(US8802686, 2 | US8802686, C2)
Affinity DataIC50:  4nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM6131(US8802686, 1 | US8802686, C1)
Affinity DataIC50:  6nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105239(US8580782, 7)
Affinity DataIC50:  6nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129351(US8802686, 9)
Affinity DataIC50:  6nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM6192(US8802686, 3 | US8802686, C3)
Affinity DataIC50:  8nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM6145(US8802686, 2 | US8802686, C2)
Affinity DataIC50:  8nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84541(Indirubin derivative, 22)
Affinity DataIC50:  10nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105239(US8580782, 7)
Affinity DataIC50:  10nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106952(US8592581, 3)
Affinity DataIC50:  10nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105236(US8580782, 4)
Affinity DataIC50:  11nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129350(US8802686, 8)
Affinity DataIC50:  11nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129348(US8802686, 6)
Affinity DataIC50:  12nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM6192(US8802686, 3 | US8802686, C3)
Affinity DataIC50:  12nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129354(US8802686, 12)
Affinity DataIC50:  12nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM6131(US8802686, 1 | US8802686, C1)
Affinity DataIC50:  16nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106953(US8592581, 4)
Affinity DataIC50:  20nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106950(US8592581, 1)
Affinity DataIC50:  20nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84539(Indirubin derivative, 36 (X=O))
Affinity DataIC50:  20nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105234(US8580782, 1)
Affinity DataIC50:  20nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105237(US8575203, I-4 | US8580782, 5)
Affinity DataIC50:  21nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129349(US8802686, 7)
Affinity DataIC50:  21nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129346(US8802686, 4)
Affinity DataIC50:  21nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105235(US8580782, 3)
Affinity DataIC50:  24nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129355(US8802686, 13)
Affinity DataIC50:  25nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105234(US8580782, 1)
Affinity DataIC50:  29nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105238(US8575203, I-5 | US8580782, 6)
Affinity DataIC50:  29nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50358213(CHEMBL1922219 | US8846696, (2R3S)-3-{9-Isopropyl-6...)
Affinity DataIC50:  30nMpH: 7.4Assay Description:The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhi...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105235(US8580782, 3)
Affinity DataIC50:  32nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129347(US8802686, 5)
Affinity DataIC50:  36nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106956(US8592581, 7)
Affinity DataIC50:  40nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84536(Indirubin derivative, 32)
Affinity DataIC50:  40nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84535(Indirubin derivative, 8)
Affinity DataIC50:  40nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84555(Indirubin derivative, 30a | Indirubin derivative, ...)
Affinity DataIC50:  40nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106960(US8592581, 11)
Affinity DataIC50:  40nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84542(Indirubin derivative, 23)
Affinity DataIC50:  40nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106958(US8592581, 9)
Affinity DataIC50:  40nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105240(US8580782, 10)
Affinity DataIC50:  42nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129352(US8802686, 10)
Affinity DataIC50:  43nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM129357(US8802686, 15)
Affinity DataIC50:  49nMpH: 8.0 T: 2°CAssay Description:CDK2/CycE (50 mg/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106959(US8592581, 10)
Affinity DataIC50:  50nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106961(US8592581, 12)
Affinity DataIC50:  50nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM106955(US8592581, 6)
Affinity DataIC50:  50nMpH: 7.5 T: 2°CAssay Description:To evaluate the in-vitro kinase potency of the compounds, they were screened against CDK 2 and CDK9. Kinase assays were performed in 96-well plates u...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM105238(US8575203, I-5 | US8580782, 6)
Affinity DataIC50:  64nMpH: 8.0Assay Description:CDK2 kinase assays (either cyclin A or cyclin E-dependent) were performed in low protein binding 96-well plates (Corning Inc., Corning, N.Y.).More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84553(Indirubin derivative, 28a | Indirubin derivative, ...)
Affinity DataIC50:  70nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM84546(Indirubin derivative, 27a | Indirubin derivative, ...)
Affinity DataIC50:  70nMpH: 8.0 T: 2°CAssay Description:Inhibition assay using CDK and selective kinases such as gsk3, EGFR, c-Kit, InsR and KDR.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM27216((2R)-2-({6-[(3-chlorophenyl)amino]-9-(propan-2-yl)...)
Affinity DataIC50:  70nMpH: 7.4 T: 2°CAssay Description:Inhibition of human Src kinase activity by ARIAD compounds were measured in a homogeneous time-resolved fluorescence resonance energy transfer (TR-FR...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50358211(CHEMBL1922212 | US8846696, (3S)-3-{9-Isopropyl-6-[...)
Affinity DataIC50:  70nMpH: 7.4Assay Description:The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM180819(US9133171, 24)
Affinity DataIC50:  73nMpH: 8.0 T: 2°CAssay Description:Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose aff...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 316 total ) | Next | Last >>
Jump to: